MA35601B1 - Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 - Google Patents

Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Info

Publication number
MA35601B1
MA35601B1 MA36620A MA36620A MA35601B1 MA 35601 B1 MA35601 B1 MA 35601B1 MA 36620 A MA36620 A MA 36620A MA 36620 A MA36620 A MA 36620A MA 35601 B1 MA35601 B1 MA 35601B1
Authority
MA
Morocco
Prior art keywords
hydroxymethyl substituted
compounds
pyrrolotriazines
alk1 inhibitors
alk1
Prior art date
Application number
MA36620A
Other languages
English (en)
Inventor
Jurgen Klar
Verena Voehringer
Joachim Telser
Mario Lobell
Frank Submeier
Volkhart Min-Jian Li
Michael Bottger
Stefan Golz
Dieter Lang
Karl-Heinz Schlemmer
Thomas Schlange
Andreas Schall
Wenlang Fu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47436537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35601B1 publication Critical patent/MA35601B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention porte sur de nouvelles pyrrolo[2,1-f][1,2,4]triazin-4-amines 5-substituées par (hydroxyméthyl)aryle représentées par la formule (i), sur des procédés pour la préparation de tels composés, sur des compositions pharmaceutiques contenant de tels composés et sur l'utilisation de tels composés ou de telles compositions pour le traitement de troubles liés à l'angiogenèse, en particulier de troubles oculaires liés à l'angiogenèse.
MA36620A 2012-03-27 2013-12-27 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 MA35601B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12161547 2012-03-27
PCT/EP2012/062366 WO2013004551A1 (fr) 2011-07-01 2012-06-26 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Publications (1)

Publication Number Publication Date
MA35601B1 true MA35601B1 (fr) 2014-11-01

Family

ID=47436537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36620A MA35601B1 (fr) 2012-03-27 2013-12-27 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Country Status (25)

Country Link
US (1) US9040691B2 (fr)
EP (1) EP2726482B1 (fr)
JP (1) JP5955953B2 (fr)
KR (1) KR20140036269A (fr)
CN (1) CN103764657B (fr)
AP (1) AP3529A (fr)
AR (1) AR087017A1 (fr)
AU (1) AU2012280508A1 (fr)
BR (1) BR112014000049A2 (fr)
CA (1) CA2840518A1 (fr)
CO (1) CO6870031A2 (fr)
CU (1) CU20130170A7 (fr)
DO (1) DOP2013000300A (fr)
EA (1) EA023775B1 (fr)
EC (1) ECSP13013120A (fr)
ES (1) ES2598027T3 (fr)
GT (1) GT201300313A (fr)
IL (1) IL229533A0 (fr)
MA (1) MA35601B1 (fr)
MX (1) MX2013014315A (fr)
PE (1) PE20140570A1 (fr)
PH (1) PH12013502695A1 (fr)
SG (1) SG195100A1 (fr)
UY (1) UY34167A (fr)
WO (1) WO2013004551A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834164A1 (fr) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Benzoxazinones fusionnees comme modulateurs de canal ionique
NO3175985T3 (fr) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
AU2012294342B2 (en) 2011-08-10 2017-07-27 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
JP5985658B2 (ja) * 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
WO2015157644A1 (fr) 2014-04-10 2015-10-15 Lankenau Institute For Medical Research Méthodes et compositions pour le traitement de maladies et de troubles oculaires
WO2015181097A1 (fr) 2014-05-28 2015-12-03 Bayer Cropscience Ag Procédé de préparation de dérivés de thiazole
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
JP2017535573A (ja) 2014-11-25 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピリドベンゾジアゼピノン誘導体およびそれの使用
CN107531697A (zh) 2015-04-16 2018-01-02 默克专利股份公司 3‑(1h‑苯并咪唑‑2‑基)‑1h‑吡啶‑2‑酮衍生物
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
SI3687996T1 (sl) 2017-09-27 2022-04-29 Incyte Corporation Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
MD3813800T2 (ro) 2018-06-29 2025-10-31 Incyte Corp Formulări de inhibitor al AXL/MER
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
EP4114401A1 (fr) 2020-03-06 2023-01-11 Incyte Corporation Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60026297T2 (de) * 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. Pyrrolotriazin kinasehemmer
PL213095B1 (pl) 2002-08-08 2013-01-31 Kissei Pharmaceutical Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CA2627839C (fr) 2005-11-02 2014-08-19 Bayer Healthcare Ag Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
EP1873157A1 (fr) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines et sels de ceux-ci, compositions pharmaceutiques contenant ces composes, procedes de preparation associes, et leur utilisation
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
SI2114980T1 (sl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
ES2375425T3 (es) * 2007-07-26 2012-02-29 Novartis Ag Compuestos org�?nicos.
BRPI0817434A2 (pt) * 2007-10-17 2015-06-16 Novartis Ag Composto orgânicos
WO2009140128A2 (fr) * 2008-05-13 2009-11-19 Irm Llc Composés et compositions servant d'inhibiteurs de kinases
EP2424368B1 (fr) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Composés de pyrrolotriazine

Also Published As

Publication number Publication date
AP2014007378A0 (en) 2014-01-31
PH12013502695A1 (en) 2019-06-14
US20140256718A1 (en) 2014-09-11
AP3529A (en) 2016-01-11
EP2726482B1 (fr) 2016-07-20
NZ619453A (en) 2016-01-29
DOP2013000300A (es) 2014-02-28
KR20140036269A (ko) 2014-03-25
PE20140570A1 (es) 2014-04-28
IL229533A0 (en) 2014-01-30
MX2013014315A (es) 2014-01-31
EA201490103A1 (ru) 2014-06-30
ECSP13013120A (es) 2014-02-28
ES2598027T3 (es) 2017-01-24
CU20130170A7 (es) 2014-04-24
CA2840518A1 (fr) 2013-01-10
AR087017A1 (es) 2014-02-05
US9040691B2 (en) 2015-05-26
SG195100A1 (en) 2013-12-30
EP2726482A1 (fr) 2014-05-07
UY34167A (es) 2013-01-31
BR112014000049A2 (pt) 2017-02-07
CN103764657B (zh) 2016-05-25
WO2013004551A1 (fr) 2013-01-10
JP2014525902A (ja) 2014-10-02
AU2012280508A1 (en) 2013-12-12
JP5955953B2 (ja) 2016-07-20
EA023775B1 (ru) 2016-07-29
CN103764657A (zh) 2014-04-30
CU24146B1 (fr) 2016-02-29
CO6870031A2 (es) 2014-02-20
GT201300313A (es) 2014-11-13

Similar Documents

Publication Publication Date Title
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA32965B1 (fr) Derives de sulfonamides
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA34308B1 (fr) Triazolopyridines substituées
CA2878796C (fr) Derives de pyridinone comme inhibiteurs de la transglutaminase tissulaire
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA49127B1 (fr) Dérivés d'indole n-substitués
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA52375A1 (fr) Inhibiteurs de cdk8/19